Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · IEX Real-Time Price · USD
1.670
-0.040 (-2.34%)
At close: Jul 19, 2024, 4:00 PM
1.700
+0.030 (1.80%)
Pre-market: Jul 22, 2024, 7:16 AM EDT
Cyclacel Pharmaceuticals Stock Forecast
CYCC's stock price has decreased by -85.51% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CYCC stock has a target of 11, which predicts an increase of 558.68% from the current stock price of 1.67.
Analyst Consensus: Buy
* Price targets were last updated on May 3, 2024.
Analyst Ratings
The average analyst rating for CYCC stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $21 → $11 | Strong Buy | Maintains | $21 → $11 | +558.68% | May 3, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 19, 2023 |
| Roth MKM | Roth MKM | Strong Buy Maintains $16 → $21 | Strong Buy | Maintains | $16 → $21 | +1,157.49% | Dec 19, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $120 | Buy | Maintains | $120 | +7,085.63% | May 25, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $150 → $120 | Buy | Maintains | $150 → $120 | +7,085.63% | Mar 7, 2023 |
Financial Forecast
Revenue This Year
60.69K
from 420.00K
Decreased by -85.55%
Revenue Next Year
102.00K
from 60.69K
Increased by 68.07%
EPS This Year
-5.03
from -26.75
EPS Next Year
-4.41
from -5.03
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 124,950 | 105,000 | 21.0M | 114.6M | 167.9M |
| Avg | 60,690 | 102,000 | 20.4M | 111.3M | 163.1M |
| Low | n/a | 98,000 | 19.6M | 106.9M | 156.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -70.3% | 73.0% | 20,528.4% | 460.5% | 50.9% |
| Avg | -85.6% | 68.1% | 19,939.2% | 444.5% | 46.6% |
| Low | - | 61.5% | 19,152.9% | 423.1% | 40.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.85 | -1.77 | 0.20 | 8.15 | 12.40 |
| Avg | -5.03 | -4.41 | 0.19 | 7.92 | 12.05 |
| Low | -7.01 | -6.82 | 0.19 | 7.60 | 11.57 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 4,104.3% | 56.7% |
| Avg | - | - | - | 3,984.2% | 52.2% |
| Low | - | - | - | 3,824.0% | 46.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.